FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Crucell reports early-stage success with TB vaccine

Tools
  • Email
  • Print
  • Comment
  • Contact Author

Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. The Dutch biotech is teamed up with the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative in advancing AERAS-402/Crucell Ad35. And a third early-stage vaccine trial is underway in South Africa, which has an extraordinarily high rate of the disease. The currently used vaccine, Bacille Calmette-Guerin, was developed 85 years ago, but is regarded as largely ineffective against pulmonary TB.

"While preliminary, these results are promising. We are pleased that Crucell's technologies are playing a key role in the search and development of a much-needed TB vaccine," said Dr. Jaap Goudsmit, chief scientific officer at Crucell. "We highly value the collaboration with Aeras and SATVI on this important mission."

- see the release
- read this report

Related Articles:
In surprise move, Crucell dumps West Nile program
Crucell, MedImmune strike deal
Crucell acquires SBL Vaccin for €39.4M. Report

More stories about Tuberculosis   Tuberculosis Vaccine   Crucell   Jaap Goudsmit   South Africa  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 52 + 11?
To combat spam, please solve the math question above.